Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Volastra Therapeutics

Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
From Volastra Therapeutics
Via Business Wire
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb
From Volastra Therapeutics
Via Business Wire
Volastra Therapeutics Co-founder Samuel Bakhoum to Deliver Plenary Presentation at American Association for Cancer Research Annual Meeting 2021
From Volastra Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.